Research doesn’t happen in one lab.
The Leong Team’s work depends on institutional infrastructure at MGH and Broad, and on international genetics consortia that make ancestrally diverse, adequately powered studies possible.
The infrastructure behind our studies.
Diabetes Research Center
The clinical home base for this team’s human studies — nurses, coordinators, and clinic space for the visits that TARGET, CGM-A1c Genetics, COVID, and PROGRESS all depend on.
Center for Genomic Medicine
MGH’s home for genomic research, including the Florez Lab, where several current and former team members and collaborators are based.
Mass General Brigham Biobank
The genotyped biobank this team recalls participants from for recall-by-genotype studies like TARGET and CGM-A1c Genetics — identifying people at the extremes of genetic risk directly from real-world clinical data.
Trans-Omics for Precision Medicine (TOPMed)
An NIH program integrating whole-genome sequencing with other omics data across diverse cohorts; Dr. Leong holds a collaborative role within TOPMed’s broader genetics efforts.
Where the genetic discovery work happens at scale.
MAGIC
An international consortium pooling GWAS data on glycemic traits — the source of much of the HbA1c and glycemic-trait genetics this team’s work builds on.
EDIC
The long-term follow-up of the landmark DCCT trial. Dr. Leong is Principal Investigator of the MGH site, studying the long-term outcomes of type 1 diabetes.
Broad Institute
Home to several current and former team members and close collaborators, including Dr. Josep Mercader’s group, who co-author much of this team’s genetics work.
MVP
A U.S. Department of Veterans Affairs genomics cohort of over a million veterans, providing scale and diversity for genetic association studies of diabetes-related traits.
CHARGE
A consortium of longitudinal cohort studies used for large-scale genetic discovery in cardiometabolic and aging-related traits.
DIAGRAM
An international consortium focused on discovering and replicating genetic variants associated with type 2 diabetes across ancestries.
NUS
An international academic partner extending this team’s genetics and precision-medicine research to additional ancestrally diverse populations.
